whoa. whoa. whoa.

You're being directed to the ELOCTATE Healthcare Professional website. If you're okay with that, we're okay with that.

Come back soon!

Meet Real People

Meet Real People

NEARLY 3000 people have chosen to count on ELOCTATE.*

Meet the ELOCTATE Peers, hear their stories, and learn why they count on the bleed protection offered by ELOCTATE prophylaxis.

*Data on file. Waltham, MA; Bioverativ Therapeutics Inc., a Sanofi company.

ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

WE’RE IN THIS TOGETHER

Hear practical insights from ELOCTATE Peers on what to expect from in-person and tele-medicine appointments, how to remain active, and how to stay busy in the current environment.

Chayse Photo

Chayse counts on ELOCTATE for overall bleed protection. After all, Chayse knows while he keeps the rhythm going, he’s protected from bleeds.

SEE CHAYSE’S STORY >
Craig Photo

Craig and his doctor chose prophy with ELOCTATE to protect his body and his joints from bleeds after treating on demand for decades.

SEE CRAIG'S STORY >
DJ Photo

Eloctate helps keep DJ's joints protected from bleeds as he drums to a rhythm.

SEE DJ'S STORY >
Jonathan Photo

Jonathan switched from ADVATE® to ELOCTATE.

SEE JONATHAN'S STORY >
Jenny Photo

Jenny wants to protect her son's joints from bleeds now, and as he gets older.

SEE THEIR STORY >
Chet Photo

When it comes to joint bleed protection, Chet’s son Caleb gets the coverage he needs on the court.

SEE THEIR STORY >
Kenny Photo

Kenny keeps his body and joints protected from bleeds on the road with ELOCTATE.

SEE KENNY'S STORY >

Note: Patient stories reflect the real-life experiences of ELOCTATE users and their caregivers. However, individual experiences may vary. Patient stories are not necessarily representative of what another person using ELOCTATE may experience. Talk to your healthcare provider about what's right for you. ELOCTATE Peers have been compensated for sharing their stories.

The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body's individual response.

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.

Resources You Can Count On

ELOCTATE provides extensive resources and support you can count on whether you’re considering a switch, just getting started, or a long-time ELOCTATE user.

financial assistance

financial assistance programs

Specialized programs help eligible patients access treatment.

explore programs >
support product education

product education

Step-by-step instructions to infuse and reconstitute safely and confidently.

instructions for use > reconstitution video >
support connection

connection

Connect to local Community Relations and Education Managers and your healthcare team.

find your core > microhealth app >

Become an ELOCTATE Peer

Are you currently on ELOCTATE and want to share your story with others?

Email us

GOT MORE QUESTIONS? CONTACT YOUR CoRe.

Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.

GET ME TO THE CoRe LOCATOR

IMPORTANT SAFETY INFORMATION AND INDICATIONS

+

IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.

Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.

If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.

These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.

INDICATIONS

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

PLEASE SEE FULL PRESCRIBING INFORMATION

MANUFACTURED BY

Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.